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Heroin addiction is devastating to both the person addicted and to
society. Attempts to treat heroin addiction have proved difficult due to the
extreme addictive qualities of the drug. Medication-assisted recovery or
pharmacotherapy, such as methadone and buprenorphine, are controversial in
that it is providing a medication that has similar qualities of heroin itself.
Behavioral treatments alone have limited success due to many factors. The
literature presented will provide a look at heroin and heroin addiction, as well
as a comprehensive study of outpatient treatments that are currently being
used. The purpose of this study is to determine the most effective way to treat
heroin addiction as the number of overdoses and death are on the rise.
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CHAPTER ONE
STATEMENT OF DEFENSE OF PROBLEM
Introduction
Heroin is an extremely addictive drug and has been determined one of the most
devastating and destructive drugs that a person can use: to the person addicted and to society.
Due to the extremely addictive qualities of the drug, it makes treating heroin addiction a difficult
task. As heroin was once marketed as a miracle drug and thought to be safer than morphine, it
has been proven that it is not a miracle drug; its use is a public health concern, as well as a
significant burden to society. Not only is heroin addiction a physical illness that affects the
central nervous system, it is responsible for annual treatment costs in the billions of dollars and a
low success rehabilitation rate. Millions of people all over the world are addicted to heroin with
limited effective treatment to achieve abstinence. With abstinence difficult to achieve, is harm
reduction by way of pharmacotherapy or behavioral therapies the way to treat heroin addiction?
It is important to explore the many ways that heroin can impact lives and society, and to
determine how pharmacotherapy and behavioral therapies have been used to attempt control
heroin addiction. This study will take a comprehensive look at heroin addiction and current
treatment available. Pharmacotherapy will be explored due to its harm reduction versus
abstinence controversy, as well as behavioral therapies. Due to the millions of people that
continue to use the drug despite the level of destruction it has the potential to cause, it is essential
to continue to explore treatment modalities, regardless of controversial opinions.
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Background to the Problem
To understand the difficulty in the treatment of heroin addiction, it is important to first
know what heroin is and its etiology in an attempt to better understand how it has impacted
American and worldwide history. Santella (2007) reported that heroin is a derivative of the
opium poppy and that the cultivation of the opium poppy is the oldest drug that has ever been
cultivated and even existed prior to the fermentation of alcohol. The author stated that its origin
comes from a specific poppy plant called Papaver somniferum and is known for its euphoric and
analgesic properties. Its earliest cultivation has been highly disputed with one of the earliest
known places of cultivation in lower Mesopotamia, which is now Iraq in c.3400 B. C. and then
spread to Egypt, Rome, Persia (Iran), India, Greece, China, etc. and over centuries, has made a
global sweep across the planet (Santella, 2007). Santella reported that throughout the centuries,
opium became both an international and domestic commodity with the exploitation of opium by
Portugal in the late 1400s to the move into Britain and America in the 1800s. The market for
opium was massive and established through trade, consumption, and drug wars due to the
irresistibility of the drug for both its addictive qualities and lucrative money-making
opportunities. The drug was originally marketed for its medicinal qualities, but soon was known
for its addictive qualities. Opium, that could grow almost anywhere, was considered the perfect
product for trade (Santella, 2007).
From that time, many changes took place regarding the composition and administration
of opium in the modern era. Santella (2007) reported that in 1803 the British scientist, Serturner,
isolated the active ingredient in opium and called it morphine. This discovery enabled scientists
to better control the drug’s effects in terms of treating pain and illness. He stated that in 1827, the
hypodermic needle was invented that would administer the drug by injecting it directly into the
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bloodstream. This was a pivotal discovery for the administration of pain medication during war
time, but increased the potency and possibility of developing a dependence on the drug (Hanson,
Venturelli, and Fleckenstein, 2006). Another discovery in 1874 by British scientist, C. R. Wright,
would alter the future in a most dramatic way; he synthesized morphine by boiling it with acetic
acid and called it heroin or diacetylmorphine (Santella, 2007). The author stated that C. R.
Wright had no way of knowing at that time that heroin would become one of the century’s most
dangerous and lethal drug. In 1895, The Bayer Co. began production of diacetylmorphine and
called it heroin, as a substitute for morphine. According to Hanson, Venturelli, and Fleckenstein
(2006), by 1900 there was an estimated 1 million Americans that were addicted to opiates with
many of these being soldiers that had returned from the war addicted to heroin.
As the drug grew in popularity, laws were enacted in an attempt to control the alarming
rate of heroin addiction. In 1914, the Harrison Act was passed to regulate opium and its products.
In 1924, heroin was banned by the United States to be used for any medicinal purpose (Hanson,
Venturelli, and Fleckenstein, 2006). The drug that was first introduced as a cough syrup and an
aid to combat other drug addiction was now considered to be a danger to a person’s health and
well-being. War and use of drugs during war added to the use of heroin and other drugs. The
authors stated that the Vietnam War increased the heroin addiction in the United States due to
40% of soldiers that used heroin to combat the stress that accompanied an unpopular war. A
smaller percentage continued to use heroin after they had returned to the United States and was
significant enough to add to the rising heroin-addicted population (Hanson, Venturelli, and
Fleckenstein). Even though heroin had been banned to be used medically, the popularity for the
drug by persons addicted remained popular due to the addictive qualities of the drug. In a review
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article by Doran (2008), he reported that 80 million people worldwide are abusing heroin and
other opiates to date and that figure is a conservative estimate of the prevalence.
Significance of the Study
It has been discussed where and what heroin was derived from and determined that it has
a significant global impact on society, but it is also important to explain what heroin actually is
and how it impacts a person, both physically and psychosocially. Why does a person want to
engage in the use of a drug that has the potential to have such profound negative consequences?
The answer is that heroin also has profound positive consequences: euphoria. Once a person has
used heroin, the person has a feeling of euphoria, a profound feeling of well-being or elation.
Heroin and other opiates affect the “pleasure system” in the brain involving several brain
chemicals called neurotransmitters which include dopamine and endorphins (LeVert, 2006).
Dopamine and endorphins are naturally occurring chemicals in the brain and can alter the natural
process the brain uses to communicate with the rest of the body. LeVert explained that the
human brain and the nervous system create an extensive communication network that affects all
aspects of the body’s functions, such as emotions, actions, and physiological functions. She
stated these functions are processed through the brain and nerve fibers that extend to the spinal
cord and to the body. Each section of the brain is responsible for certain activities. For instance,
the cerebral cortex is the largest section and responsible for “thinking” activities, including
thought perception, memory, and communication (LeVert, 2006). LeVert reported that other
parts of the brain control the physiological functions, such as breathing, blood pressure, etc. The
brain must communicate with the body by sending messages from one cell to another. This
process is made possible by neurons or cells of the nervous system. Neurons are made of a cell
body, dendrites, and the axon. The message travels down the dendrite to the cell body, the
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message is processed and it moves out to the axon. Between the end of the axon and the
neighboring neuron, there is a gap called the synapse. Before the message can cross over into the
dendrites of the neighboring neuron, neurotransmitters or natural chemicals are released so that
the message can cross the synapse and bind to receptors. Neurotransmitters and receptors work
like a lock and key; neurotransmitters are the key and the receptors are the lock. Once the lock is
open, the message has been completed. The use of heroin and other opiates have the potential to
interfere and possibly permanently alter this communication network (LeVert, 2006).
LeVert (2006) reported that endorphins, endephalins, and dynorphin are the
neurotransmitters mostly affected by opiates, especially heroin. They are known as endogenous
or “internally-occurring opiates” and regulate such functions such as mood control and immune
system responses. LeVert stated that the reason the potency of heroin and other opiates affect a
person in such a profound way is that they bind to the same receptors as the endogenous opioids:
affecting the body in widespread areas. Endorphins are a chemical the brain manufactures to
provide respite to a person when they experience pain or stress. Endorphins flood the area
between the nerve cells and allow what is called the “firing of the nerve impulse” which in turn
creates a pain relief affect (LeVert, 2006). The other neurotransmitter that is severely affected by
the use of heroin and other opiates is dopamine, the main element the body needs to feel
pleasure. LeVert explained that opiates create an increase of a heightened feeling of pleasure and
gives a person a false feeling of well-being. The author stated that in addition to the pleasure
system of the brain affected by heroin and other opiates, respiration is also affected. This
explains the use of the opiate codeine used in cough medication due to the slowing of respiration.
Used to excess, respiration is compromised and death is imminent. The brain’s vomiting center is
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triggered by opiate use due to the tendency for nausea or vomiting as a result of opiate use
(LeVert, 2006).
LeVert (2006) reported that heroin comes in a powder form and in different colors: white,
pink, gray. The author reported the different colors are due to the impurities or additives left over
from production and that the darkest form of heroin is called “black tar.” There are many ways
that heroin can be ingested: injection, smoking, snorting, swallowing, and rarely, in tablet form.
LeVert reported the injection of heroin gives the highest level of euphoria due to the drug being
directing injected into the blood stream. LeVert stated that the powder is mixed with citric acid
and heated; creating a liquid that can be loaded into a syringe and injected under the skin, called
a “skin pop”, into the vein, or into the muscle. She implied the injection of the drug gives the
most euphoric, longest lasting effect of the drug, with the effect being felt as soon as 7-8 seconds
from injection and lasting as long as 5 hours, depending on the dosage. The author also described
smoking the powder form of heroin by melting it on a foil and inhaling it from a straw or tube.
The drug is absorbed through the blood vessels in the lungs and reaches the brain in 10-15
minutes. LeVert reminded her readers that this is most commonly known as “chasing the
dragon.” Another form of administration is snorting or sniffing the powder through a straw or
tube into the nose. The heroin is absorbed through the blood vessels of the nose and its effects
are felt within 10-15 minutes. Smoking and snorting heroin are thought to be the least risky of
administrations due to reducing the chances of being exposed to the HIV virus or hepatitis; most
commonly contracted by way of injection.
The euphoric feeling that using heroin can give a person is a major reason that the drug
can be so addicting but there are other physical reactions the body has to the use of the drug. It
was earlier reported that the use of heroin most often causes a trigger to the vomiting/nausea
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center of the brain. LeVert (2006) reported that many deaths from the use of heroin are caused by
a person aspirating on their own vomit during use. Once a person gets past the vomiting/nausea
sensation, a person will feel the “rush” that lasts a few seconds and this leads to “on the nod”
(LeVert), which is a wakeful and drowsy state, and the “high” that can last up to five hours.
Once tolerance builds up, the rush and the high are not as intense as it was when they first began
using the drug.
The opiate-addicted person using heroin will continue using to avoid the negative effects
of withdrawal from the drug. LeVert reported that a person that is addicted to heroin that does
not continue to use the drug will encounter flu-like symptoms due to withdrawal such as, nausea
and vomiting, muscle pain, weakness, and irritation. A person that is dependent on the drug,
heroin, will most often use again to avoid feeling the negative effects of withdrawal and will use
any means available to obtain and use the drug again, regardless of the consequences. This is an
area of societal concern due to the increased crime rate associated with heroin use.
On September 1, 2011, the National Drug Control Policy (ONDCP) reported that the
Nation’s criminal justice system is a revolving door in regard to the consequences of drug use
and is one of the most significant challenges we face. Some of these challenges are crimes that
are committed to support a drug habit. The Bureau of Justice (BJS) (2011) reported that as much
as 18% of state and federal inmates committed their crimes, such as home invasion, prostitution,
theft, domestic abuse, due to getting the drug or under the influence of a drug. Doran (2008)
reported that on the average, a heroin user is 40-60% most likely to engage in criminal behavior
when they are not incarcerated on in treatment. Doran stated that his findings have shown that
treatment lessens the tendency for heroin addicts to commit crimes. Treatment, therefore, is
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paramount: for both the health and welfare of the person who is heroin-addicted and society as a
whole.
In addition to drug-related crimes, persons that are addicted to heroin will have other
aspects of their life impacted, both physically and behaviorally. After a person uses heroin for a
period of time, the following physical and behavioral symptoms will increase in frequency:
cravings, tolerance builds up and leads to increased use; flu-like withdrawal symptoms when the
person is without the drug; unsuccessful attempts at controlled use; time spent obtaining, using,
and recovering from drug use which takes time away from other aspects of life that should be
priority; occupational, recreational, and social activities that are given up due to use; and
continued use despite the physical, psychological issues that are worse due to use. Also, public
health issues are created as a result of heroin use, especially when it is administered by injection.
These issues are HIV/AIDS and hepatitis due to sharing needles with persons that are infected,
high-risk behavior while a person is under the influence, submitting to a lifestyle that is risky,
such as prostitution and promiscuity, and the always possible fatal overdose. The National
Institute for Drug Abuse (NIDA) (2010) stated the drug also affects all areas of the body over
time due to toxic contaminants, such as lungs, liver, kidneys, or brain, causing permanent
damage to vital organs. The authors stated that 70-80% of all new hepatitis infections are a direct
result of intravenous drug use. LeVert (2006) reported that the lining of the heart is often
damaged due to the additives that heroin is often cut with.
Along with the societal issues, such as drug-related crimes, and the physical effects of the
use of heroin, there is also the issue of costs to society. Schilling et al. (2006) estimated that
untreated heroin and other opiate dependence is responsible for $1.2 billion per year deficit on
the health care system due to more extreme health care needs, as well as poorer health outcomes
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than that of the general population. HIV/AIDS, Hepatitis C, and sexually transmitted diseases are
some of the biomedical conditions that are prevalent in association with heroin use
Purpose and Objectives of the Paper
It is evident to see the seriousness of this public health concern and the need to find the
most effective treatments available to treat this disease. Is abstinence possible for the majority of
those in treatment or should the goal be to assist those in treatment with harm reduction? Peele
(2002) reported that harm reduction changes the focus from expecting abstinence to assisting a
person to have a better quality of life and reduce harm. Peele reported this idea of moving clients
to a better place in their life promotes to protect drug users (and non-drug users exposed to drug
users) from the worst consequences. Pharmacotherapy is a form of harm reduction and has been
used to treat heroin addiction, including detoxification using methadone, buprenorphine, and
other medications. Other forms of harm reduction are to provide clean needles and information
about risky behavior. Behavioral therapies are also used to aid in treatment of heroin addition,
such as cognitive behavioral therapy and motivational interviewing. This study will show the
treatments that are currently being used, the effectiveness of the treatments, and what research is
being conducted to improve better treatment outcomes.
Definition of terms
Administration: Otherwise known as route of administration-the path or method of taking a drug
into the body.
Agonist: chemical that binds to the receptor of a cell and triggers a response by that cell.
Analgesic: A group of drugs that facilitate the reduction of pain.
Antagonist: chemical that acts within the body to reduce the physiological activity of another
chemical substance.
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Buprenorphine: A semi-synthetic opiod used to block the opiod receptor and reduce withdrawal
symptoms.
Endogenous: Produced or grown within.
Euphoria: It is an emotional state that gives an intense sense of well being.
Harm Reduction: The practical strategies that reduce the negative consequences of drug use.
Methadone: A synthetic opiate that was designed to reduce/eliminate the use of illicit heroin and
other opiates.
Modalities: The models of treatment used.
Neurotransmitter: Endogenous chemicals that transmit signals from the neuron to the target cell
across a synapse.
Pharmacotherapy: The treatment of disease through the administration of drugs.
Tolerance: A need for markedly increased amounts of the drug to achieve the desired effect.
Tolerance denotes a physiological dependence.
Withdrawal: Physiological dependence symptoms, such as extreme pain, chills, diarrhea,
tremors, flu-like symptoms, cramps, etc.
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CHAPTER TWO
OVERVIEW OF LITERATURE
There are numerous approaches of pharmacotherapy and behavioral therapies that have
been used in the past to treat heroin addiction: some more successful than others. Effective
treatment has long been an issue for researchers and treatment providers due to the difficulty for
heroin addicts to achieve the ultimate goal of abstinence. There are multiple variables that play a
role in this difficulty, such as limited access to methadone clinics, poor economic status of
persons’ addicted, and a diminishing state and national budget for mental health and substance
abuse treatment, including residential and outpatient treatment. Pharmacotherapy is controversial
in the rehabilitation field due to the use of medications, with some of the same properties of
opiates, to decrease withdrawal symptoms of opiate addiction and used in a tapering off program.
Wesson and Smith (2010) reported that there is a controversy surrounding the different
modalities of treatment: most wrestle between complete abstinence versus harm reduction. Peele
(2002) reported that it replaces the abstinence or zero-tolerance policy with a plan that seeks to
better protect the addict from the worst consequences. Behavioral therapies alone do not have a
history of successful outcomes for persons addicted to heroin. For this study, information will be
presented that will give an overview of the most used methods in an attempt to determine the
best method for better outcomes.
Pharmacotherapy
Methadone Maintenance Therapy (MMT)
There are many studies and ideas of the effectiveness of MMT for the treatment of heroin
and other opiate addiction. For as many people that support the use of MMT, there are as many
against the use of MMT. Those that proclaim that methadone is the one and only effective
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medication-assisted treatment for heroin addiction often do so because it has been the standard in
the treatment of heroin addiction and the most researched for many years. Those that suggest that
the use of methadone, that is a synthetic version of heroin, is treating one drug addiction with the
use of another drug of possible addiction. Despite the controversy of the use of methadone as a
treatment for heroin addiction, there are few alternatives to choose from.
The National Institute of Health (NIH) (2009) reported that methadone is marketed by
names such as Dolophine and Methadose and was first introduced into the United States in 1947
by the Eli Lilly and Co as an analgesic. It was not used as a treatment for heroin addiction until
1964. The Substance Abuse and Mental Health Services Administration (SAMHSA) (2009)
reported that methadone is a synthetic agent and full agonist that bind to the same receptor site as
heroin and other opiates. As a result, methadone blocks the euphoric and sedating effects that
persons using heroin and other opiates experience. Taking methadone is reported to relieve
craving and withdrawal symptoms that are common with heroin addiction. The authors reported
that when used appropriately, methadone is an effective and safe treatment for opiate addiction.
Schilling, Dornig, and Lungren (2006) also reported that when used as intended, methadone is
safe and effective, and seen as favorable due to respect of cost and keeping people in treatment
for longer period of times. The authors reported that when a person is receiving MMT in a
methadone clinic, in order to continue to receive their dosage, a federally regulated periodic
random drug screen is required and helps track the patients over time, which assists with
measuring safety and effectiveness. Part of the issue, and thus part of the controversy, is that
methadone is not always used as intended and prescribed.
Schilling et al. (2006) stated that methadone shares many of the same effects of that of
heroin, such as addiction, sedation, and respiratory issues when used in higher doses and when
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abused. Roche, McCabe, and Smyth (2008) stated that “street” methadone is obtained for many
reasons. The authors reported that some of the reasons are as follows: they have never enrolled in
MMT and are buying it illegally off the street; they do not feel their dosage is adequate for their
cravings and/or withdrawal; or for hedonic reasons. The authors commented that while using
methadone obtained illegally is not without risks, it is preferred to heroin use.
Roche et al. (2008) revealed that of the opiate-related deaths in Dublin, 54% of those
deaths were related to methadone. SAMHSA (2009) authors reported that although deaths as a
result of methadone use is difficult to determine due to a lack of standardized medical examiner
techniques, it is known that the increase in deaths due to methadone use is part of an increase in
poisoning deaths. Most of these deaths are due to unintentional drug overdoses. SAMHSA
reported that according to data from the National Center for Health Statistics that from 1999 to
2005, there was an increase of 468% of methadone-related poisoning deaths. Although this
figure is staggering, methadone-related deaths are still below the number of persons that die from
the use of heroin (SAMHSA).
Jimenez-Trevino et al. (2011) conducted a study that followed up on patients that were
admitted to MMT for the first time and they found that at a 15-year follow-up that 60.4% of
those that survived were still enrolled in MMT. The authors also noted that at a 25-year followup, the death rate was 49.5%. Although the authors admit there are limitations of the study, such
as missing data on causes of death, the percentage of death is very high. This is not to suggest
that MMT is the cause of the deaths, but that for those that use heroin, overdoses on heroin and
methadone, as well as HIV/AIDS and hepatitis C, are common and rising.
While methadone-related overdoses and deaths are among the issues facing users; there
are also physiological issues to deal with as well. Dutra et al. (2008) reported that patients that
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are engaged in stable methadone maintenance will still remain vulnerable to drug-related cues
and triggers right before expected dosage time which implicates that dependency to methadone
could be an issue. The question remains whether MMT is effective enough in the treatment of
heroin addiction to take the chance with a person also becoming addicted to methadone. Wang,
et al. (2010) determined it is for this reason they felt compelled to study the brain through MRI
imaging to further understand the neurobiological response to drug cues and further the
development of alternative therapies and improve effectiveness of already existing MMT
therapies. Their study results concluded that despite long-term MMT, even persons in recovery
for heroin addiction are still susceptible to learned brain response. Mattick, Breen, Kimber, and
Davoli (2009) conducted a study that compared MMT to no opiod replacement therapy and
found that MMT keeps people that are dependent on heroin in treatment programs longer and
with a reduction of their use. A once-a-day dose last four to six times longer than the effects of
heroin and is reported to be medically safe, even when used up to 10 years.
Langleben et al. (2008) suggested that while they agree that MMT is the standard agonist
therapy for heroin addiction, significant heroin use while in MMT is still an issue. The objective
of their study was to determine if environmental drug-related cues were implicated in illicit
heroin use while in MMT. The authors reported that their study, using magnetic resonance
imaging (MRI), shows that methadone has the potential to cause an intense trigger or craving for
heroin. The author’s findings concur with Dutra et al. in suggesting that patients in a stable
methadone maintenance program are still vulnerable to drug cues and that vulnerability is the
highest right before the expected dose of methadone.
Wesson and Smith (2010) reported that in the United States, methadone has been
restricted to specialized drug treatment clinics that are under oversight by federal and state
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agencies. They stated that other than these clinics, it was prohibited to treat heroin or other opiate
addictions with controlled substances. Methadone clinics are not plentiful in rural areas, which is
an issue with the typical person that is addicted to heroin due to their psychosocial status because
of the lifestyle they are most likely forced to live. As already reported, there is a history of
persons becoming addicted to methadone, while not in a clinical treatment program, which
obtain the medication in an illegal manner, trading a heroin addiction for a methadone addiction.
The use of methadone was intended to be used while gradually reducing the dosage and to
eliminate dependency (Falvo, 2009). Methadone Maintenance has received negative feedback
and stigma due to illegally obtained methadone use and the lack of gradual reduction of use.
According to Dr. John A. Peterson, during a seminar (IAODAPCA Fall Conference) at the Rend
Lake Resort and Conference Center in Whittington, IL, the use of methadone has been
negatively presented and that the only difference in methadone and buprenorphine (which will be
discussed in the next section) is that buprenorphine is presented in a more positive light due to
being prescribed by a physician (personal communication, November 2, 2010). He suggested
that methadone is effective, affordable, and more easily accessed. Schilling et al. (2006) reported
that they believe that methadone is underused. This may be due to the stigma attached to MMT,
as well as the lack of adequate facilities in rural areas. Due to the difficulty in treating persons
that are addicted to heroin and other opiates, and although there is controversy to the most
effective pharmacotherapy, MMT is still the standard treatment.
Buprenorphine Maintenance
Another medication-assisted recovery program is the use of buprenorphine. In 2001, as a
result of the Narcotic Addict Treatment Act, an exemption to the restriction that methadone was
placed was altered and buprenorphine was approved for the treatment of opiate addiction
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(Wesson and Smith, 2010). Wesson and Smith reported that buprenorphine and any products that
contain buprenorphine (marketed as Subotex and Suboxone) were approved to be prescribed by
“qualified” physicians. Buprenorphine is a Schedule III-V medication that was approved by the
Food and Drug administration for the treatment of opiate dependence. The authors reported that
as of 2009, there are as many as 13,150 doctors that were approved to administer buprenorphine
and able to treat 30 patients, with another 2,500 that could treat 100 patients at a time.
Wesson and Smith (2010) reported that buprenophine is a semi-synthetic opiate that was
created in the late 1960s by Reckitt and Coleman (a pharmaceutical company). It was originally
intended to be an analgesic and in 1978 marketed an injectable form called Buprenex. The
authors stated that in the late 1970s the drug was presented as a treatment for opiate addiction.
While sublingual tablets were introduced in 2002 with dosages of 2 mg and 8 mg, the sublingual
film was approved in 2010 and is reported to be faster to dissolve and have a better taste than the
tablets. Wesson and Smith reported that Subutex is buprenophine alone while Suboxone is a
combination of buprenophine and naloxone. Its use is intended to be administered while a person
is in moderate withdrawal. The naloxone is a narcotic antagonist that is added to the
buprenorphine to prevent the abuse or misuse of the medication. This means that if a person is
actively using heroin and ingests Suboxone, it will put a person in immediate withdrawal
(Wesson and Smith). This suggests that Suboxone has an advantage over methadone in that it is
not as easily abused.
Wesson and Smith conducted a study in a 90-day detoxification with 45 heroin-addicted
subjects, double-blind, double-dummy, and found that there was no differences between
buprenorphine and methadone in terms of retention, drug use, or symptoms. The authors stated
that the only advantage to use buprenorphine may be that qualified physicians can prescribe the
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medication while those using methadone either use a methadone clinic or obtain it illegally.
Petitjean, et al. (2001) had similar findings in a double-blind trial comparing buprenorphine and
methadone. Although they reported to have limitations in their study, their conclusion was that
when taking into consideration less duration of treatment, less withdrawal symptoms, and less
dosing, buprenorphine has more advantages.
The injectable form of buprenophine, Buprenex cannot be legally prescribed for the
treatment of opiate addiction because it was approved for the treatment of pain, not opiate
addiction. Wesson and Smith (2010) reported that Buprenorphine Maintenance with sublingual
buprenorphine has a better potential in regard to societal acceptance than methadone for the
following reasons:
•

Buprenorphine is less intense in regard to physical dependence than a full opiate agonist.

•

It is thought to be safer if it were ingested in an overdose.

•

It can be prescribed by qualified physicians.

The authors reported that the duration of buprenorphine maintenance typically last one to two
years for intravenous drug users. This is contingent on other changes in the addicted person’s
life, such as changes in friends, developing activities to replace the time spent in drug use, and
continue with additional psychosocial treatment (Wesson & Smith). Wesson and Smith reported
that an extended period of maintenance is most effective for the majority of persons addicted to
opiates. This extended period of time is intended to ensure that changes in lifestyle have been
achieved so that long-term abstinence can be maintained. As with methadone, there is abuse
potential for the use of buprenorphine. Some opiate abusers dissolve the sublingual tablets and
inject the solution as a replacement for heroin (Wesson & Smith). As reported earlier, Suboxone,
buprenorphine with naloxone, reduces this abuse potential. Also with methadone maintenance,
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buprenorphine maintenance was also designed for a gradual reduction of dosage to facilitate
future abstinence.
Centers for Substance Abuse Treatment (CSAT) (2004) reported that buprenorphine
dosing occurs on a less frequent basis than a full agonist, such as methadone, and can be given
more infrequently than methadone. While methadone is dosed daily, buprenorphine can be given
three times a week. The authors stated that the side effects are similar to methadone, such as
nausea, vomiting, and constipation, with the effects not as severe. There are, however, issues
with the taste of buprenorphine; when administered sublingually, the taste is reported as very
strong and pungent (CSAT). When taken in the tablet form, it slows the effect than when taken
sublingually. This issue may be instrumental in persons to cease taking the drug and return to
heroin use.
Detoxification
While detoxification is ideally the first step in any treatment program, sometimes heroin
addiction has more challenges than other drug dependence in regard to the physical addiction to
heroin and the severe withdrawal symptoms when the drug is not being used. Falvo (2009)
reported that detoxification is ultimately to initiate abstinence while reducing the symptoms of
withdrawal. Due to the seriousness of withdrawal symptoms when endured without a step-down
program (such as with methadone and buprenorphine), medical management by a facility that is
trained with heroin withdrawal is important. Medical management may consist of treating
dehydration, electrolyte balance, administration of vitamins and other nutrients, and monitoring
for other complications (Falvo). Falvo reported that Clonidine (Catapres), a non-opiate based
mediation, also helps block withdrawal symptoms and is sometimes used during the
detoxification process. Clonodine, as well as methadone and buprenorphine must be gradually
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decreased during the withdrawal period to avoid adverse consequences. NIDA (2005) reported
that acute withdrawal symptoms are the most severe for 48-72 hours after the last opiate
ingestion and will dissipate after 7-10 days. The author reported that a general feeling of anxiety
and restlessness, as well as craving will most likely remain for a longer period of time.
Other periods of detoxification may be the result of drug-related crimes in which the
person that is using heroin is forced to cease use due to being incarcerated. This forced
abstinence is most often unpleasant at best. Most judicial system facilities do not offer any form
of medication to assist with withdrawal symptoms.

Depot Naltrexone, Clonodine, Naloxene, Lofexidine
NIDA (2005) reported the use of other medications that are used to reduce the severity of
withdrawal symptoms while either being in a detoxification program or while in an inpatient
treatment facility. These medications, referred to as antagonists, are used to block the effects of
the use of opiates. Each of the medications is different but serves primarily the same purpose.

Behavioral Therapies
Cognitive Behavioral Therapy (CBT)
In the early 1960s, Dr. Aaron Beck developed a form of psychotherapy called cognitive
behavioral therapy (CBT). The concept of the therapy is that irrational or dysfunctional thoughts
lead to problematic behaviors (Beck, 2011). Beck reported that every person has a belief system
which influences the way they think and behave. She stated that a person can learn to evaluate
their thinking in a more realistic way and make decisions based on rational thoughts. Beck
reported that CBT has been extensively tested since 1977 and 500+ outcome studies have
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demonstrated efficacy in a wide range of psychiatric disorders. Beck contended that CBT is an
effective therapy for many disorders, including substance abuse, but did not specify if CBT alone
would be effective for active heroin addiction due to the many areas that heroin addiction effects,
such as biomedical, environmental, etc. Much of the literature suggested that CBT is an effective
therapy to work with persons that have substance abuse and addiction issues but due to the
seriousness and difficulty of treating persons with heroin addiction, CBT alone has not proven
effective. For instance, Preda and Duneyevich, (2012) supported the idea that CBT alone is not
adequate treatment for persons in active heroin addiction. They reported that CBT is effective
along with medically managed treatment, as well as relapse prevention and aftercare. They
contend that group therapy, using cognitive behavioral skill, is quite effective in addressing the
psychosocial aspects of drug addiction. Amato et al. (2009) reviewed 11 studies that involved
1592 patients and found that psychosocial therapy used in conjunction with a pharmacological
therapy, regardless of the kind of psychosocial therapy, reduced patient dropouts, decreased
heroin use while in treatment, decreased recidivism to further use, and decreased absences from
treatment.
Contingency Management (CM)
Another form of behavioral treatment that is used for the treatment of heroin addiction, as
well as other forms of addiction, is contingency management. Contingency management is
derived from a form of operant conditioning. Stanger and Budney (2010) reported that CM is
based on the principal that when a person uses a drug, that person will receive a positive
reinforcement from using the drug, such as the “high” or the relief from withdrawal. The positive
reinforcement of not using the drug, or abstinence, is better health, improved quality of life, etc.
which takes longer to achieve. The authors reported that under these circumstances, motivation
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will gravitate to drug use due to the instant gratification. CM is used to offer a desired
consequence, such as vouchers to exchange for goods, access to affordable housing, decreased or
dropped legal charges (such as in drug court), etc. in exchange for the targeted behavior, such as
abstinence. Greenweld (2008) stated that CM has demonstrated the ability to facilitate abstinence
from opiates, but that CM was not used as a treatment alone: it was used in conjunction with
pharmacotherapy. Greenwald reported that there is an issue that when contingency management
has been discontinued, relapse to the drug remains a challenge. The author conducted a study
that provided a CM component to an existing pharmacotherapy program and found that the CM
demonstrated a significantly more effective treatment than with pharmacotherapy alone. As with
CBT, research shows that CM used alone with pharmacological treatment has limited
effectiveness. Other potential barriers to using CM are the cost of items, goods, services,
vouchers, etc, costs of frequent urinalysis, and training of staff for delivering CM to patients.
Motivational Interviewing (MI)
MI is a form of behavioral therapy that is based on Bill Miller’s concept that a person
who is ambivalent about change can be motivated to change by providing a direct, clientcentered counseling style (Miller and Rose, 2009). The authors stated that resistance to change is
not challenged but that the counselor that uses MI will roll with resistance in an empathetic
manner. This counseling style was originally developed to work with persons with substance
abuse problems but has been tested to be effective for a wide range of targeted behavior (Miller
and Rose). The authors reported that research has shown that it decreases maladaptive behaviors
as well as increases the desire for positive changes. Miller and Rose reported that the MI
therapist style has the potential to improve client treatment outcomes because it sets the stage for
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the client to enter treatment. The author’s stated that three decades of research clearly show that
MI is evidenced –based and diverse in its use.
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CHAPTER THREE
DISCUSSION AND IMPLICATIONS
Summary of Key Findings
The goal of the paper was to present a better understanding of the devastating effects of
heroin addiction that is due to heroin’s extremely addictive qualities and the negative
consequences that extend beyond the individual user, such as crimes committed to obtain the
drug, limited support system due to use, etc. By understanding the effects, it clarifies the urgency
of determining the best treatment options for the heroin user.
Treatment for heroin addiction has proven difficult at best due to the highly addictive
qualities of the drug. Pharmacotherapy medication, such as methadone and buprenorphine, and
behavioral therapies, such as CBT and CM, were presented to inform the reader of the
interventions being used to combat the disease of heroin addiction. Used separately, each of the
treatment modalities fails to treat all complex components of heroin addiction.
The use of pharmacotherapy is controversial in that some researchers believe that the
medications used have enough similarities to the heroin, that it is assisting a person that already
has one addiction, in developing another addiction. Despite the long-time controversy of the use
of pharmacotherapy, the medications have proven to block the effects of heroin and other
opiates, as well as eliminating serious withdrawal symptoms (NIDA, 2005). Schilling et al.
(2006) reported concerns that methadone and buprenorphine can also be abused and illegally
obtained, but that pharmacotherapy, when used as prescribed and under controlled care, are
instrumental in allowing the addicted person to return to functioning.
A history of the source of methadone was presented so that a clearer picture of the
medication can be understood as a treatment for heroin addiction. Schilling et al. (2006) provided

24

information that reported the effectiveness of the use of methadone, as well as what they feel is
the underutilization of the drug, possibly due to stigma and too few clinics in rural areas. They
reported that methadone can be effective to block the withdrawal and cravings symptoms if used
as prescribed and under supervision. The authors also stated that there is a propensity to abuse
methadone due to several reasons: they have never enrolled in MMT and are buying it illegally
off the street; they do not feel their dosage is adequate for their cravings and/or withdrawal; or
for hedonic reasons. SAMSHA (2009) offered statistics for those that abuse methadone as having
an increase of 468% of methadone-related deaths from 1999 to 2005 suggesting that methadone,
while effective, must be used as prescribed and under close monitoring.
Buprenorphine was offered as another form of medication-assisted treatment for persons
with heroin addiction. A brief history of its introduction as a pharmacological treatment and
information about dosage and effectiveness were also presented. While buprenorphine is also an
effective medication used to combat heroin addiction and has some advantages over methadone,
such as less frequent dosing and gastrointestinal side effects not as severe, CSAT (2009) stated
that there are disadvantages as well. These include pungent after taste of sublingual
administration and slower effect rate when taken in tablet form. Buprenorphine also has
properties that facilitate abuse. Suboxone, buprenorphine and naloxone, help eliminate the abuse
due to naloxone’s agonistic properties (Wesson and Smith).
The use of pharmacotherapy might be effective in reducing withdrawal symptoms and
block the effects of the use of heroin, but it does not change the psychosocial aspects of a
person’s life, such as where they live, existing support system, health concerns, etc. These areas
of life have the potential to facilitate continued abstinence or to allow the person addicted to
return to heroin use. Once a person has become abstinent from heroin, there are other changes
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that must be made to ensure the person does not return to the use of the drug. Some of these
changes are to change the place of residence if it is an unstable environment for recovery, change
the people that the person associated with, obtain and maintain employment, etc., as well as
identifying triggers, challenge irrational thoughts, and develop a support system. These support
systems could be reconnection with family, spiritual affiliations, Narcotics Anonymous, and
other 12-step support groups. These issues can be addressed with cognitive behavioral therapy or
one of the other behavioral therapies.
Beck (2011) reported that CBT can be instrumental in assisting clients to maintain
abstinence. Preda and Duneyevich (2011) agreed that CBT is helpful to change thinking and
behavior, but when used alone, without other interventions, is not effective enough to achieve
abstinence. The same could be said about contingency management and motivational
interviewing. Both are effective in assisting and motivating a person to change behavior, but
used alone do not effectively address the physical aspects of heroin addiction.
Conclusion
While the information presented reported the positive and negative aspects of the
pharmacological approach to the treatment of heroin addiction, such as medication-assisted
recovery, there was no clear reasoning that pharmacotherapy alone is effective to maintain
abstinence for those with heroin addiction. It helps with the physical withdrawal and cravings
which is essential to abstinence, but it does not ensure the person will remain abstinent. Many
aspects of life have to change in order to improve treatment outcomes. The literature reported the
positive aspects of using cognitive behavioral therapy as a way of treating a person in regard to
the psychosocial aspects of addiction, such as environmental, socioeconomic, and behavioral
issues, but do not aid in the physical aspects of withdrawal and cravings. The implications of
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these facts suggest that both treatments in conjunction with one another would produce the most
effective treatment outcomes. This is not to say that it is feasible in respect to cost to society in
regard to public health care and sufficient provisions available. Heroin addiction is a physical
addiction that affects their psychosocial environment and for a person to have the best treatment
outcome, it is my opinion that both pharmacotherapy, along with a behavioral therapy be
utilized.
Implications
The implication of the facts presented, regarding the most effective treatment for persons
addicted to heroin, are intended for researchers and treatment providers (rehabilitation
counselors), as well as other agencies that might work with this population, such as social
workers. The most important implication is for researchers who dedicate their careers in
determining the most effective treatment for persons addicted to heroin, and then for the
treatment providers that rely on the researchers to provide the most up-to-date research and
findings for evidence-based practice. The research shows that pharmacotherapy is more effective
when used along with a behavioral therapy.
Researchers have studied the effects of the use of methadone for many years. Long-term
methadone maintenance (10 years or more), such as is reported by NIDA (2005) do not seem to
embrace the idea of decreasing the dosage over time to achieve complete abstinence from heroin
as well as methadone. The ideal scenario is for the person addicted to heroin to achieve
abstinence from the drug completely, in a timely manner, while increasing knowledge of their
addiction and the recovery process. In other words, they need to learn how to live life on a daily
basis without the drug. Methadone, buprenorphine, or other medication-assisted recovery
methods could assist with physical withdrawal and cravings while the person is receiving a
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behavioral therapy by way of outpatient counseling, both individual and group. Unfortunately,
this ideal scenario involves many agencies, many resources, and willingness on the part of the
person who is addicted to heroin. There is also the issue of a continued decrease of mental health
and substance abuse funding available and it is unlikely that the majority of persons addicted to
heroin are in the position to carry health insurance.
As a rehabilitation counselor, it is important to determine the most effective treatment for
the person that is addicted to heroin. It would be ideal to know that treatment works, but it seems
from the literature that current treatment works, under the right conditions. Unfortunately, for
most, the right conditions are not always available. The stigma that is attached to heroin
addiction does not lend itself to social acceptance and there are a vast number of people that look
at heroin addiction as a moral flaw instead of a deadly disease. To help change this view of the
heroin addict might generate more support in finding a more effective form of treatment.
Recommendations
Current medications being used to assist with withdrawal and cravings, have their own
addictive properties, so future research could attempt to isolate a medication that has antiaddictive properties. There is currently a drug being used in other countries that has antiaddictive qualities but is banned in the United States due to the hallucinogenic properties.
Donnelly (2011) reported that ibogaine is used in many other countries as an effective
medication to use for serious drug addictions, such as with opiates. Ibogaine is a naturally
occurring psychoactive drug that is made from the root of the Tabernanthe iboga shrub in West
Africa (Donnelly). While it has been used for centuries for spiritual ceremonies, it has also been
used for medicinal purposes.
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Donnely reported that it was discovered in 1962 that ibogaine alleviated the craving for
heroin during an experiment that included a group of college students, with seven of them being
heroin addicts. The experiment was to determine the therapeutic value of hallucinogenic drugs
(they were not illegal at this time) in which they inadvertently discovered that ibogaine actually
relieved their craving for heroin. Donnely stated that one of the students, Lotsof, ceased using
heroin and all other drugs, as well as most of the other members of the group that were addicts,
during the six months that followed the initial dose of ibogaine.
Donnely expressed her dismay at the drug being pulled from the United States market
during the 1960s. The author stated that the studies that were conducted on ibogaine showed
great promise of alleviating and eliminating craving so the addict can focus on the psychosocial
changes needed to be made in their life. She stated that it was due to the extreme effectiveness of
ibogaine that the drug was made illegal; pharmaceutical companies have decreased clientele
when a drug eliminates the problem.
The drug is considered a Schedule I controlled substance in the United States and is
argued that the hallucinogenic properties cause the drug to have no medicinal value, and in fact
causes safety concerns (Donnely). She stated that studies have shown the drug effective enough
for more research to be conducted to find a way to isolate the effective part of the shrub and
eliminate the hallucinogenic properties. It is her opinion that sadly, there simply is no profit to be
made on a drug that only has to be ingested one-two times to show significant decrease in
symptoms, and therefore does not warrant further research or study.
It is very disheartening when a drug that is proven effective cannot be used due to the
lack of monetary value. It is understandable to raise questions about the use of ibogaine due to
the safety concerns of using the drug in its present state, but it is extreme to not explore the
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possibilities that the drug can bring to the heroin addict. If the drug were removed from the
Schedule I list of medications, it could be considered for research. While is not considered a cure
for heroin addiction, the drug has the potential to give the addict hope for recovery and a future.
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